Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBP-6000 (Sublocade) Extension Study in Opioid Use Disorder
NCT02896296Phase 3Completed
- Sponsor
- Indivior
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of buprenorphine extended-release injection in opioid use disorder (OUD), sponsored by Indivior. Started Aug 2016; status: completed.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02896296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02896296.